Psychopharmacology therapy recommendations for patients with the COVID-19

With the spread of COVID-19, some patients with psychiatric disorders have been infected, and their psychiatric symptoms could be fluctuated the pneumonia illness. Besides, a variety of psychiatric symptoms could also be induced by COVID-19 and antiviral drugs-related side effects (e.g., interferon), which might lead to the poorer outcomes of patients and should be treated. Considering the poor physical conditions due to the COVID-19 in pneumonia patients, the tolerability and safety issues of the psychotropic drugs and the potential interactions between psychotropic drugs and antiviral drugs are important clinical challenges. With the systematical review of the up-to-date clinical data and treatment guidelines, this article provides a detailed introduction of the tolerability of psychotropic drugs in patients with COVID-19, the interactions between psychotropic drugs and other kinds of drugs and the precautions for psychotropic drugs use in special populations.